Literature DB >> 14499632

Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor.

Belinda E Peace1, Kara J Hill, Sandra J F Degen, Susan E Waltz.   

Abstract

Heterogeneous receptor-receptor interactions may play a role in intracellular signaling. Accordingly, the interaction of two dissimilar tyrosine kinase receptors, Ron and epidermal growth factor receptor (EGFR) was investigated. The functional interaction of Ron and EGFR in cell scatter and oncogenic transformation was investigated in vivo. Transfection of a dominant negative form of EGFR into human embryonic kidney cells stably expressing Ron (293-Ron) dramatically reduced the scatter response induced by the Ron ligand hepatocyte growth factor-like protein/macrophage stimulating protein (HGFL). The scatter response of the 293-Ron cells was also attenuated by treatment of the cells with the specific EGFR inhibitor AG 1478. Co-transfection of Ron and dominant-negative EGFR, or co-transfection of EGFR and a dominant-negative form of Ron reduced focus formation in NIH/3T3 cells. Western analysis of NIH/3T3 cells overexpressing murine Ron and expressing endogenous levels of EGFR was used to demonstrate that Ron and EGFR co-immunoprecipitate. Stimulation of the cells in vitro with the Ron ligand HGFL or with the EGFR ligand epidermal growth factor (EGF) appeared to induce phosphorylation of both receptors. Co-immunoprecipitation and phosphorylation of phosphatidyl inositol 3-kinase (PI3-K) was also observed. This novel finding of a functional and biochemical interaction between Ron and EGFR suggests that heterologous tyrosine kinase receptor interactions may play a role in cellular processes such as scatter and transformation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499632     DOI: 10.1016/s0014-4827(03)00280-5

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  32 in total

1.  The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome.

Authors:  Peter T Yu; Michele Babicky; Dawn Jaquish; Randy French; Karly Marayuma; Evangeline Mose; Sherry Niessen; Heather Hoover; David Shields; David Cheresh; Benjamin F Cravatt; Andrew M Lowy
Journal:  Int J Cancer       Date:  2012-03-08       Impact factor: 7.396

2.  Isolation of Fully Human Antagonistic RON Antibodies Showing Efficient Block of Downstream Signaling and Cell Migration.

Authors:  Zeynep Gunes; Adriana Zucconi; Mario Cioce; Annalisa Meola; Monica Pezzanera; Stefano Acali; Immacolata Zampaglione; Valeria De Pratti; Luca Bova; Fabio Talamo; Anna Demartis; Paolo Monaci; Nicola La Monica; Gennaro Ciliberto; Alessandra Vitelli
Journal:  Transl Oncol       Date:  2011-02-01       Impact factor: 4.243

3.  Loss of Ron receptor signaling leads to reduced obesity, diabetic phenotypes and hepatic steatosis in response to high-fat diet in mice.

Authors:  William D Stuart; Nicholas E Brown; Andrew M Paluch; Susan E Waltz
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-02-03       Impact factor: 4.310

4.  IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration.

Authors:  Dawn V Jaquish; Peter T Yu; David J Shields; Randall P French; Karly P Maruyama; Sherry Niessen; Heather Hoover; David A Cheresh; Ben Cravatt; Andrew M Lowy
Journal:  Carcinogenesis       Date:  2011-05-11       Impact factor: 4.944

Review 5.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

6.  The RTK Interactome: Overview and Perspective on RTK Heterointeractions.

Authors:  Michael D Paul; Kalina Hristova
Journal:  Chem Rev       Date:  2018-12-27       Impact factor: 60.622

7.  Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines.

Authors:  Rebecca J McClaine; Aaron M Marshall; Purnima K Wagh; Susan E Waltz
Journal:  Neoplasia       Date:  2010-08       Impact factor: 5.715

8.  Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.

Authors:  Todd W Bauer; Fan Fan; Wenbiao Liu; Marjorie Johnson; Nila U Parikh; Graham C Parry; Jennifer Callahan; Andrew P Mazar; Gary E Gallick; Lee M Ellis
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

Review 9.  Met-related receptor tyrosine kinase Ron in tumor growth and metastasis.

Authors:  Purnima K Wagh; Belinda E Peace; Susan E Waltz
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

Review 10.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.